Clinical Trial Update: Pharmacokinetics (PK) of Dalfampridine-ER 7.5 mg BID in Healthy Volunteers and Subjects With Mild or Moderate Renal Impairment [Phase 1]

View source ↗

Summary

This Phase 1 study investigates the pharmacokinetics of dalfampridine-ER 7.5 mg taken twice daily in healthy volunteers and in people with mild or moderate rena…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Kidney Disease

Drugs mentioned

• Dalfampridine-ER (dalfampridine)

Snippet

Sponsor: Acorda Therapeutics | Conditions: Renal Insufficiency | Phase 1 | Status: COMPLETED | Results posted: 2012-11-07